Lo Vecchio Andrea, Liguoro Ilaria, Dias Jorge Amil, Berkley James A, Boey Chris, Cohen Mitchell B, Cruchet Sylvia, Salazar-Lindo Eduardo, Podder Samir, Sandhu Bhupinder, Sherman Philip M, Shimizu Toshiaki, Guarino Alfredo
Section of Pediatrics, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
Department of Clinical and Experimental Medical Sciences, University Hospital of Udine, Udine, Italy.
Vaccine. 2017 Mar 14;35(12):1637-1644. doi: 10.1016/j.vaccine.2017.01.082. Epub 2017 Feb 16.
Rotavirus (RV) is a major agent of gastroenteritis and an important cause of child death worldwide. Immunization (RVI) has been available since 2006, and the Federation of International Societies of Gastroenterology Hepatology and Nutrition (FISPGHAN) identified RVI as a top priority for the control of diarrheal illness. A FISPGHAN working group on acute diarrhea aimed at estimating the current RVI coverage worldwide and identifying barriers to implementation at local level.
A survey was distributed to national experts in infectious diseases and health-care authorities (March 2015-April 2016), collecting information on local recommendations, costs and perception of barriers for implementation.
Forty-nine of the 79 contacted countries (62% response rate) provided a complete analyzable data. RVI was recommended in 27/49 countries (55%). Although five countries have recommended RVI since 2006, a large number (16, 33%) included RVI in a National Immunization Schedule between 2012 and 2014. The costs of vaccination are covered by the government (39%), by the GAVI Alliance (10%) or public and private insurance (8%) in some countries. However, in most cases, immunization is paid by families (43%). Elevated cost of vaccine (49%) is the main barrier for implementation of RVI. High costs of vaccination (rs=-0.39, p=0.02) and coverage of expenses by families (rs=0.5, p=0.002) significantly correlate with a lower immunization rate. Limited perception of RV illness severity by the families (47%), public-health authorities (37%) or physicians (24%) and the timing of administration (16%) are further major barriers to large- scale RVI programs.
After 10years since its introduction, the implementation of RVI is still unacceptably low and should remain a major target for global public health. Barriers to implementation vary according to setting. Nevertheless, public health authorities should promote education for caregivers and health-care providers and interact with local health authorities in order to implement RVI.
轮状病毒(RV)是全球范围内引起肠胃炎的主要病原体,也是儿童死亡的重要原因。自2006年以来已有轮状病毒免疫接种(RVI)可用,国际胃肠病学、肝病学和营养学会联合会(FISPGHAN)将RVI确定为控制腹泻病的首要任务。一个FISPGHAN急性腹泻工作组旨在评估全球当前的RVI覆盖率,并确定地方层面实施过程中的障碍。
向各国传染病专家和卫生保健当局发放了一份调查问卷(2015年3月至2016年4月),收集有关地方建议、成本以及对实施障碍的看法等信息。
79个被联系国家中的49个(回复率62%)提供了完整的可分析数据。49个国家中的27个(55%)推荐了RVI。虽然有5个国家自2006年以来就推荐了RVI,但大量国家(16个,33%)在2012年至2014年期间将RVI纳入了国家免疫规划。在一些国家,疫苗接种费用由政府承担(39%)、由全球疫苗免疫联盟承担(10%)或由公共和私人保险承担(8%)。然而,在大多数情况下,免疫接种费用由家庭支付(43%)。疫苗成本高昂(49%)是实施RVI的主要障碍。疫苗接种费用高昂(rs=-0.39,p=0.02)以及家庭承担费用(rs=0.5,p=0.002)与较低的免疫接种率显著相关。家庭(47%)、公共卫生当局(37%)或医生(24%)对RV疾病严重程度的认识有限以及接种时间(16%)是大规模RVI项目的进一步主要障碍。
RVI引入10年后,其实施率仍然低得令人无法接受,应继续作为全球公共卫生的主要目标。实施障碍因环境而异。尽管如此,公共卫生当局应促进对护理人员和卫生保健提供者的教育,并与地方卫生当局互动,以实施RVI。